Ketamine is the one psychedelic-family treatment that is broadly legal in the US with a prescription. This directory lists the more-established at-home telehealth programs, in-clinic IV/IM infusion providers, and the Spravato (esketamine) REMS network.
The largest at-home sublingual-ketamine telehealth platform; clinician evaluation, lozenge shipment, and guided at-home sessions with optional integration coaching.
Out-of-pocket; HSA/FSA eligible. Screens out high-risk cardiac and psychotic histories.
Psychiatrist-led at-home ketamine program with bundled therapy sessions and integration coaching; frequently accepts some in-network insurance coverage.
Low-dose daily sublingual ketamine under medical supervision; positioned at a lower price point than session-based models.
Daily micro-dose protocol; different evidence base than the session-based Phase 2-style approach.
At-home sublingual ketamine with integration coaching; emphasizes structured 4-session programs.
Nationwide in-clinic ketamine IV and IM infusions; Stella acquired the US Field Trip clinic portfolio in 2023-2024.
One of the older dedicated ketamine-infusion clinic networks, with psychiatry-led protocols and formal outcome tracking.
Long-running IV-ketamine clinic; published outcome research; integration-oriented protocols.
FDA-approved esketamine nasal spray for treatment-resistant depression and depression with acute suicidal ideation. Must be administered in a REMS-certified site; patient observed for 2 hours after dosing. The only ketamine-family therapy with broad insurance coverage.
Typically covered by commercial insurance and many Medicare Part D plans after treatment-resistant depression criteria are met.
Academic center with active clinical trials of ketamine adjacent to their psilocybin work; not a general-public clinic but an option for trial participation.
Research access, not fee-for-service therapy.